Although STAT3 inhibitors are only in early stages of clinical development and have not been tested on NB models, currently there are several bioavailable PIM1 inhibitors in clinical studies, including PIM447, AZD1208, and SGI-1776 [287]. Here, PIM1 is linked to neuroblastoma.